Polyethylene Glycol Loxenatide Pharmacokinetics Study in Subjects With Normal and Insufficiency Renal Function

Type 2 Diabetes Mellitus Clinical Trial

Official title:

Kinetic Study of Human Pharmacokinetics in Normal Renal Function, and Renal Insufficiency Subject of Polyethylene Glycol Loxenatide (PEX168)(Open, Non-randomized, Parallel-group)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02467790
• Other study ID #: PEX168-Ih
• Status: Recruiting
• Phase: Phase 1
• First received: June 8, 2015
• Last updated: January 23, 2016
• Start date: February 2015
• Est. completion date: May 2016

Study information

• Verified date: January 2016
• Source: Jiangsu Hansoh Pharmaceutical Co., Ltd.
• Contact: Hao Zhang, MD
• Phone: 13975806919
• Email: zhanghaoliaoqin[@]163.com
• Is FDA regulated: No
• Health authority: China: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

To compare and analysis pharmacokinetics of PEX 168 in patients with renal insufficiency or normal renal function who were administrated subcutaneously single dose PEX168.To evaluate dose adjustment of PEX168 administered in patients with renal insufficiency and provide a scientific basis in patients with renal insufficiency of rational drug use.

Description:

This is an open, non-randomized, parallel-group, single-dose study that evaluated the pharmacokinetics of PEX168 when single dose administered with PEX168 in patients with renal insufficiency and normal renal function subjects. The total duration of each subject's participation in the study was approximately 45 days, which included up to a 14-day Screening Period, a 31-day PK sample collecting Period.

Center: This study was conducted at two sites in the Third Xiangya hospital of Center South University and Shanghai Changhai Hospital.All subjects receives a single 200μg doses of PEX168 injected subcutaneously on Day 1.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 24
• Est. completion date: May 2016
• Est. primary completion date: March 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 31 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Age 31-65 (both inclusive) years old, male or female;

2. Weight: Male =50kg, female =45kg, 18=BMI=28;

3. The Cockcroft-Gault (CG) formula to estimate creatinine clearance (CLCr), K / DOQI definition of chronic kidney disease (CKD) 2 patients: 60=CLcr=89 ml / min; chronic kidney disease (CKD) 3 patients: 30=CLcr=59 ml / min for renal insufficiency,Cockcroft-Gault (CG) formula to estimate creatinine clearance (CLCr) =90ml / min for normal subjects.

4. In the 48 hours before the start of the test to the end of the trial period, agreed to get rid of tobacco, alcohol, caffeine, fruit juice subject;

5. Understand the study procedures and methods, voluntarily participate in this experiment, and writing and signed informed consent.

Exclusion Criteria:

1. Known or suspected of GLP-1 class of drug allergy or allergy;

2. Before screening,received GLP-1 receptor agonists, GLP-1 analogs, DPP-IV inhibitors or any other similar structure of the drug treatment;

3. In addition to the induced renal dysfunction disease itself, suffering from any other organ of acute illness and those with any influence of drugs in vivo study of chronic diseases;

4. within 6 months prior to screening,having any surgery, including the impact of gastric emptying of gastrointestinal surgery;

5. Screened within the previous three months to participate in blood donation and blood donation =400mL, or who participate in blood donation or blood transfusion within one month;

6. Within 3 months before screening participated in any drug or medical device trials are (including placebo);

7. Drinking, smoking addiction, drug abuse and drug abusers;

8. In addition to judging laboratory abnormalities diagnosis of renal dysfunction caused by disease, there are other clinically significant laboratory abnormalities (Note: Patients with moderate to severe anemia (Hb <60g / L), severe hypertension ( SBP> 160mmHg and / or diastolic blood pressure> 100mmHg) patients, heart rate> 100bmp, ECG QTc> 450ms were required to exclude;

9. ALT> 1.5 times the upper limit of normal and / or aspartate transaminase> 1.5 times the upper limit of normal and / or total bilirubin> 1.5 times the upper limit of normal;

10. Fasting triglycerides> 5.64mmol / L (500mg / dl);

11. Beyond the normal range of serum amylase, and the clinical significance is determined by the investigator;

12. Pancreatitis, pancreatic cancer a history;

13. Blood thyroid stimulating hormone (TSH) beyond the normal range and clinically significant judgment by the investigator;

14. The pregnancy test was positive women of childbearing age, or pregnant women, breastfeeding women, and within six months there have been unwilling or unable to take family planning and effective contraception during the trial of male / female volunteers;

15. The hepatitis B surface antigen, hepatitis C antibody, HIV antibody, syphilis antibody test positive;

16. Researchers believe any situation that might lead to any subject can not be completed or to the subject of this study bring significant risk.

Study Design

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 2
• Type 2 Diabetes Mellitus

Intervention

Drug:
• PEX168
PEX 168: 200µg,Subcutaneous,one time.

Locations

Country	Name	City	State
China	Third Xiangya Hospital, Central South Univety	Chang Sha	Hunan

Sponsors (1)

Lead Sponsor	Collaborator
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pharmacokinetic index	Prior to administration (within 60 minutes, recorded as 0h) and after administration 24h (Day 2), 48h (Day 3), 72h (day 4), 96h (day 5), 120h (day 6 ), 144h (day 7), 216h (day 10), 312h (day 14 ), 480h (day 21), 648h (day 28), 720h (day 31) collect blood 3 ml and test serum concentrations of PEX168.	Baseline to Day31	No
Secondary	Incidence of adverse events and serious adverse events		Baseline to Day31	Yes